Stock BIOCON BIOCON LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Biocon Limited

Equities

BIOCON

INE376G01013

Biotechnology & Medical Research

Delayed NSE India S.E.
Other stock markets
 12:58:24 2024-05-29 am EDT 		5-day change 1st Jan Change
316 INR -0.57% Intraday chart for Biocon Limited +2.60% +26.56%
May. 24 INDIA STOCKS-Indian shares surrender gains as U.S. rate worries weigh RE
May. 24 Biocon Ties Up with Handok to Market Anti-Diabetic Drug Liraglutide in South Korea MT

Valuation

Fiscal Period: March 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 360,832 320,015 484,623 399,173 246,192 379,390 - -
Enterprise Value (EV) 1 356,129 329,826 481,237 420,987 399,898 315,392 510,697 498,111
P/E ratio 40.2 x 42.9 x 66.1 x 61.9 x 53.3 x 30.9 x 41.3 x 25.2 x
Yield 0.16% 0.18% - 0.15% 0.73% 0.46% 0.28% 0.63%
Capitalization / Revenue 6.54 x 5.03 x 6.82 x 4.88 x 2.2 x 2.14 x 2.36 x 1.98 x
EV / Revenue 6.46 x 5.18 x 6.77 x 5.14 x 3.58 x 2.14 x 3.17 x 2.6 x
EV / EBITDA 25.6 x 20.6 x 29.2 x 21.4 x 17.1 x 9.56 x 13.8 x 10.7 x
EV / FCF -528 x -103 x -135 x -80.8 x 156 x 32.9 x 56.8 x 24.4 x
FCF Yield -0.19% -0.97% -0.74% -1.24% 0.64% 3.04% 1.76% 4.1%
Price to Book 6.01 x 4.84 x 6.37 x 4.76 x 1.39 x 1.98 x 1.8 x 1.71 x
Nbr of stocks (in thousands) 1,181,990 1,182,830 1,185,188 1,189,431 1,193,080 1,193,988 - -
Reference price 2 305.3 270.6 408.9 335.6 206.4 317.8 317.8 317.8
Announcement Date 4/25/19 5/14/20 4/28/21 4/28/22 5/23/23 5/16/24 - -
1INR in Million2INR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: March 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 55,144 63,672 71,058 81,840 111,742 147,557 161,025 191,570
EBITDA 1 13,937 16,031 16,506 19,702 23,447 32,987 36,917 46,624
EBIT 1 9,459 10,509 9,355 11,560 12,316 17,299 21,583 31,583
Operating Margin 17.15% 16.5% 13.17% 14.13% 11.02% 11.72% 13.4% 16.49%
Earnings before Tax (EBT) 1 12,149 11,860 10,774 9,831 8,971 15,252 15,494 23,796
Net income 1 9,053 7,482 7,405 6,484 4,627 10,225 9,430 14,734
Net margin 16.42% 11.75% 10.42% 7.92% 4.14% 6.93% 5.86% 7.69%
EPS 2 7.600 6.300 6.190 5.420 3.870 8.540 7.688 12.58
Free Cash Flow 1 -675 -3,211 -3,572 -5,212 2,565 15,765 8,990 20,407
FCF margin -1.22% -5.04% -5.03% -6.37% 2.3% 10.87% 5.58% 10.65%
FCF Conversion (EBITDA) - - - - 10.94% 52.21% 24.35% 43.77%
FCF Conversion (Net income) - - - - 55.44% 166.09% 95.34% 138.51%
Dividend per Share 2 0.5000 0.5000 - 0.5000 1.500 1.458 0.8956 2.012
Announcement Date 4/25/19 5/14/20 4/28/21 4/28/22 5/23/23 5/16/24 - -
1INR in Million2INR
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: March 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 18,510 18,387 17,606 18,404 21,742 24,088 21,395 23,197 29,411 37,739 34,226 36,196 36,732 38,945 35,263
EBITDA 1 3,995 4,358 3,893 4,458 4,882 5,919 3,994 4,707 6,443 9,572 7,144 8,475 8,373 8,219 -
EBIT 1 2,132 2,515 1,945 2,443 2,825 3,797 1,819 2,399 3,432 5,935 3,564 4,572 4,553 4,102 4,730
Operating Margin 11.52% 13.68% 11.05% 13.27% 12.99% 15.76% 8.5% 10.34% 11.67% 15.73% 10.41% 12.63% 12.4% 10.53% 13.41%
Earnings before Tax (EBT) 1 2,363 3,661 1,657 2,060 2,689 3,425 1,969 2,291 -255 4,966 1,837 2,676 2,930 2,319 -
Net income 1 1,686 2,532 844 1,383 1,871 2,386 1,444 470 -418 3,132 1,014 1,652 1,808 2,164 -
Net margin 9.11% 13.77% 4.79% 7.51% 8.61% 9.91% 6.75% 2.03% -1.42% 8.3% 2.96% 4.56% 4.92% 5.56% -
EPS 2 1.400 2.120 0.7100 1.160 1.560 1.990 1.210 0.3900 -0.3500 2.620 0.8500 1.460 1.620 1.150 1.700
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 1/21/21 4/28/21 7/22/21 10/21/21 1/20/22 4/28/22 7/27/22 11/14/22 2/14/23 5/23/23 8/10/23 - - - -
1INR in Million2INR
Estimates

Balance Sheet Analysis

Fiscal Period: March 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - 9,811 - 21,814 153,706 139,220 131,307 118,721
Net Cash position 1 4,703 - 3,386 - - - - -
Leverage (Debt/EBITDA) - 0.612 x - 1.107 x 6.555 x 4.61 x 3.557 x 2.546 x
Free Cash Flow 1 -675 -3,211 -3,572 -5,212 2,565 15,765 8,991 20,407
ROE (net income / shareholders' equity) 16.1% 11.7% 10.3% 9.16% 3.52% 3.45% 4.81% 7.25%
ROA (Net income/ Total Assets) 8.16% 5.62% 4.49% 3.78% 1.28% 1.5% 1.65% 2.15%
Assets 1 110,911 133,181 164,922 171,516 362,192 632,803 571,527 685,281
Book Value Per Share 2 50.80 55.90 64.20 70.50 149.0 161.0 177.0 186.0
Cash Flow per Share 2 9.690 10.80 9.690 9.840 15.50 21.40 14.00 34.80
Capex 1 12,221 16,042 15,169 16,978 15,960 21,843 15,560 15,309
Capex / Sales 22.16% 25.19% 21.35% 20.75% 14.28% 15.06% 9.66% 7.99%
Announcement Date 4/25/19 5/14/20 4/28/21 4/28/22 5/23/23 5/16/24 - -
1INR in Million2INR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Biocon Limited

Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
19
Last Close Price
317.8 INR
Average target price
292.6 INR
Spread / Average Target
-7.91%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
BIOCON LIMITED Stock Biocon Limited
+27.28% 4.52B
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+9.83% 118B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+10.80% 106B
BIONTECH SE Stock BioNTech SE
-10.84% 23.4B
ARGENX SE Stock argenx SE
-1.69% 22.1B
GENMAB A/S Stock Genmab A/S
-10.23% 18.34B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.92% 16.59B
BEIGENE, LTD. Stock BeiGene, Ltd.
-15.11% 15.97B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+6.62% 14.03B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+17.53% 11.67B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. BIOCON Stock
  4. Financials Biocon Limited